Skip to main content
MedPathMedPath Home
Clinical Trials/DRKS00031822
DRKS00031822
Recruiting
Not Applicable

iver perfusion measurement using PCD-CT to characterize and evaluate the response to treatment of hepatocellular carcinomas of the liver as part of routine CT diagnostics and comparison with MRI liver diagnostics

niversitätsklinik Tübingen0 sites100 target enrollmentMay 15, 2023
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsK74.6Other and unspecified cirrhosis of liver

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
K74.6
Sponsor
niversitätsklinik Tübingen
Enrollment
100
Status
Recruiting
Last Updated
last year
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
May 15, 2023
End Date
TBD
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Sponsor
niversitätsklinik Tübingen

Eligibility Criteria

Inclusion Criteria

  • •Patients with liver cirrhosis and HCC\-suspect liver lesions (mainly hepatocellular carcinoma) who are before/during/after curative or palliative (systemic) therapy and patients who are about to have a liver transplant and therefore need the exclusion of HCC\-suspicious lesions.
  • •The patient's willingness to cooperate, in particular an adequate understanding of the German language.
  • •Unrestricted ability of the patient to consent.
  • •Information about the study nature of the investigation
  • •Willingness to participate in the study, which is confirmed by signature
  • •Written declaration of consent to perform a computed tomography
  • •A GFR greater than 60 mL/min. According to the current state of knowledge, the application of iodinated contrast medium to patients with a GFR \> 60 ml/min is considered harmless

Exclusion Criteria

  • •Patients with biguanide therapy (metformin in diabetes mellitus)
  • •past allergic reaction to non\-ionic contrast media
  • •Pregnancy and breastfeeding women (due to the underlying disease of the patient group to be examined (tumor disease), pregnancy should be considered unlikely. However, this is also supported by questioning the patient. For safety reasons, a pregnancy test is carried out in every questionable case).
  • •extreme obesity (body diameter \> diameter of the examination opening in the CT; currently permitted body weight 150 kg)
  • •Multiple myeloma
  • •known claustrophobia
  • •Manifest/latent hyperthyroidism (TSH basal \< 0\.2 mU/l and increase in peripheral thyroid values)
  • •Severe hepatic impairment (GOT, GPT \> 3 times normal)
  • •Heart failure NYHA III\-IV stage.
  • •Missing written declaration of consent.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
Diagnostics using perfusion CT imaging to determine the extent of bone marrow involvement of the mandible by squamous cell carcinoma - a pilot studyoral canceroral cavity carcinoma10072990
NL-OMON35141niversitair Medisch Centrum Utrecht10
Not yet recruiting
Not Applicable
A study on the usefulness of perfusion CT prescribing the amount of contrast agent by body weight in brain tumorBrain tumor
JPRN-UMIN000033531saitama medical center, saitama medical university50
Completed
Not Applicable
Detection of pseudoprogression using CT perfusion in patients with Glioblastoma Multiforme post-treatmentGlioblastoma MultiformeCancer
ISRCTN68166254The Walton Centre NHS Foundation Trust20
Completed
Not Applicable
Perfusion CT RegistryCoronary Artery Disease
NCT01696006Young-Hak Kim, MD, PhD1,059
Recruiting
Not Applicable
Perfusion CT RegistryDiseases of the circulatory system
KCT0000922Asan Medical Center2,000